Optimising Treatment of HF
Published: 21 April 2021
-
Views:
19166
-
Likes:
7
-
Views:
19166
-
Likes:
7
-
3m 2sPart 1 PART 1 – Introduction – Optimising Treatment of HF Martin R Cowie
-
10m 55sPart 2 PART 2 – A Review of Recent SGLT2 Inhibitor Data Giuseppe Rosano
-
11m 7sPart 3 PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor? Javed Butler
-
10m 59sPart 4 PART 4 – Existing HF-REF: Augmenting the SOC Shelley Zieroth
Overview
Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.
Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).
Learning objectives
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
Audience
- Heart Failure Specialists
- General Cardiologists
- Nurses
- Allied Health Professionals
More from this programme
Part 1
PART 1 – Introduction – Optimising Treatment of HF
Part 2
PART 2 – A Review of Recent SGLT2 Inhibitor Data
Part 3
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?
Part 4
PART 4 – Existing HF-REF: Augmenting the SOC
Part 5
PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?
Faculty Biographies
Martin R Cowie
Professor of Cardiology
Martin Cowie is Professor of Cardiology at King's College London, and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London, UK. Prof Cowie chairs the Clinical Practice Committee of the British Cardiac Society and sits on the UK Department of Health’s Primary Care and Heart Failure Implementation Board.
Prof Cowie's research interests focus on health technology assessment and delivery of efficient and effective care for patients with heart failure, with a focus on diagnostics, drugs, and devices. He has had a longstanding interest in evaluating remote monitoring and other digital technologies in heart failure.
Prof Cowie’s studies and reviews have been published in a variety of peer-reviewed journals, including The Lancet, European Heart Journal, British Medical Journal, Heart and International Journal of Cardiology. He is a member of the editorial boards of Heart, The British Journal of Diabetes and…
Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…